Status:
COMPLETED
Evaluation of The Effects of Nebivolol in Comparison to Atenolol on Wall Shear Stress and Rupture Prone Coronary Plaques
Lead Sponsor:
Emory University
Collaborating Sponsors:
Georgia Institute of Technology
Conditions:
Atherosclerosis
Endothelial Function
Eligibility:
All Genders
21-79 years
Phase:
PHASE4
Brief Summary
Nebivolol is a novel blood pressure lowering drug with an additional effect on the inner lining of blood vessels to release a compound called nitric oxide that can relax blood vessels. Atenolol is a b...
Detailed Description
Primary hypothesis: Nebivolol therapy will reduce the number of thin-cap fibroatheromas, VH-IVUS defined "vulnerable plaques" compared to Atenolol in patients undergoing serial angiography and IVUS. ...
Eligibility Criteria
Inclusion
- Patients with stable angina or acute coronary syndrome
- Moderate coronary lesion (defined as a lesion significant enough by the treating physician to warrant further evaluation using CFR or FFR or intravascular ultrasound assessment).
- Lesion located in the proximal 60mm of the RCA or LAD.
- On stable medical therapy for other cardiac risk factors.
Exclusion
- Left Main lesion greater than 50% stenosis
- Patients with a history of coronary artery bypass surgery
- Severe valvular heart disease
- Patients presenting with a STEMI.
- Inability to provide informed consent prior to randomization
- Creatinine \>1.5
- Lesions located beyond 60mm in an epicardial vessel
- Coronary anatomy requiring CABG
- B-blocker, calcium channel blocker or extended-release nitrate therapy within last 48 hours.
- Bradycardia (HR\<50 bpm)
- Hypotension (SBP\<100mmHg)
- Severe COPD by pulmonary function testing
Key Trial Info
Start Date :
February 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2013
Estimated Enrollment :
29 Patients enrolled
Trial Details
Trial ID
NCT01230892
Start Date
February 1 2010
End Date
September 1 2013
Last Update
February 27 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Emory University Hospital
Atlanta, Georgia, United States, 30322